Regulatory Review: Andrographis, Caffeine Warning, Biotics and More

Why It Matters

These regulatory shifts raise compliance costs and restrict market access, forcing supplement makers to redesign formulations, relabel products, and invest in safety data to stay competitive globally.

Key Takeaways

• Australia may ban Andrographis from low‑risk ingredient list by 2026
• EU still refuses probiotic health claims, limiting supplement marketing
• Six CBD novel‑food applications rejected, citing data gaps
• FSANZ requires caffeine warnings on sports foods, except non‑caffeinated sources
• Vietnam’s Decree 46 delayed, postpones stricter food‑safety inspections

Pulse Analysis

The global supplement landscape is entering a phase of heightened scrutiny, as regulators in Australia, the European Union and the United States tighten ingredient and labeling standards. In Australia, the Therapeutic Goods Administration’s proposal to drop Andrographis from the low‑risk list reflects growing concerns over severe allergic reactions, prompting manufacturers to seek alternative botanicals or provide additional safety data. Meanwhile, the EU’s steadfast refusal to approve probiotic health claims and its recent wave of CBD novel‑food rejections underscore a data‑driven approach that prioritizes consumer safety over rapid market entry, compelling companies to bolster scientific dossiers before launching new products.

Labeling and formulation strategies are also evolving. FSANZ’s new advisory and warning statements for caffeine‑containing sports foods target vulnerable groups such as breastfeeding women, yet exempt products where caffeine derives from chocolate or decaffeinated sources, creating a nuanced compliance matrix for formulators. In China, health‑food imports must now be accompanied by recommendation letters from local authorities, a measure aimed at curbing counterfeit goods but adding an extra bureaucratic layer for overseas exporters. These developments collectively raise the cost of entry and increase the importance of regulatory intelligence for brands seeking cross‑border growth.

Beyond immediate compliance, the industry is witnessing broader initiatives to strengthen safety oversight. A forthcoming global pharmacovigilance survey will engage over 200 organizations, fostering data sharing on adverse events linked to natural health products. Singapore’s Health Science Authority is urging tighter collaboration between academia and industry to navigate the complexities of the burgeoning longevity‑supplement market. Coupled with Vietnam’s delayed Decree 46, which postpones stricter food‑safety inspections, these actions signal a worldwide push toward more rigorous safety monitoring, urging companies to adopt proactive risk‑management frameworks and invest in robust scientific evidence to sustain market confidence.